Global Brain Cancer Targeted Drug Market Growth (Status and Outlook) 2025-2031

The global Brain Cancer Targeted Drug market size is predicted to grow from US$ 1574 million in 2025 to US$ 2719 million in 2031; it is expected to grow at a CAGR of 9.5% from 2025 to 2031.

A brain tumor is a mass or growth of abnormal cells in your brain. Many different types of brain tumors exist.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.

The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs.

However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need.

Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

ReportPrime's newest research report, the “Brain Cancer Targeted Drug Industry Forecast” looks at past sales and reviews total world Brain Cancer Targeted Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Brain Cancer Targeted Drug sales for 2025 through 2031.

With Brain Cancer Targeted Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Brain Cancer Targeted Drug industry.

• This Insight Report provides a comprehensive analysis of the global Brain Cancer Targeted Drug landscape and highlights key trends related to product segmentation, company formation, revenue, market share, latest development, and M&A activity.
• This report also analyses the strategies of leading global companies with a focus on Brain Cancer Targeted Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Brain Cancer Targeted Drug market.
• This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Brain Cancer Targeted Drug and breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity.

Segmentation by Type:

• Belzutifan (Welireg)
• Bevacizumab (Avastin)
• Everolimus (Afinitor)

Segmentation by Application:

• Hospital
• Retail Pharmacy
• Other

Market by Region:

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage:

• Merck & Co.
• Roche
• Novartis

Key Questions Addressed in this Report: